Until recently, our understanding of the genetic factors contributing to the pathogenesis of acute lymphoblastic leukemia (ALL) has relied on the detection of gross chromosomal alterations and mutational analysis of individual genes. Although these approaches have identified many important abnormalities, they have been unable to identify the full repertoire of genetic alterations in ALL. The advent of highresolution, microarray-based techniques to identify DNA copy number alterations and loss-of-heterozygosity in a genomewide fashion has enabled the identification of multiple novel genetic alterations targeting key cellular pathways, including lymphoid differentiation, cell cycle, tumor suppression, apoptosis and drug responsiveness. Recent studies have extended these approaches to examine the biologic basis of high-risk ALL and treatment relapse. As these techniques continue to evolve and are integrated with genome-wide epigenetic and transcriptomic data, we will obtain a comprehensive understanding of the genetic and epigenetic alterations in ALL, and ultimately will be able to translate these findings into the development of novel therapeutic approaches directed against rational therapeutic targets. Here, we review recent data obtained from genome-wide profiling studies in ALL, and discuss potential avenues for future investigation.
Acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is the commonest malignancy affecting children, 1 and is a major cause of morbidity from hematopoietic malignancies in adults. Recent decades have witnessed tremendous advances in the success of treatment of childhood ALL, with over 80% of individuals now cured. 1, 2 However, there remains considerable scope for improving treatment outcome in ALL. The majority of adult patients with ALL are not cured, 3 in part, due to an increased frequency of unfavorable genetic alterations (most notably the Philadelphia chromosome encoding BCR-ABL1). [3] [4] [5] Furthermore, up to 25% of the children and over half of the adults experience relapse, which carries a dismal prognosis. [5] [6] [7] Improvements in these outcomes by refining schedules or escalating doses of existing chemotherapeutic agents is limited by toxicity. Novel targeted therapies are urgently required in ALL to improve cure rates and reduce short-and long-term toxicities. To identify targets for new therapies, a thorough understanding of the genetic lesions contributing to establishment of the leukemic clone and resistance to therapy is required.
Both B-progenitor and T-lineage ALL are characterized by recurring chromosomal aneuploidies and translocations, detection of which is important in diagnosis and risk stratification. These include high hyperdiploidy, hypodiploidy, the translocations t(12;21)(p13;q22)[ETV6-RUNX1], t(1;19)(q23;p13.3) [TCF3-PBX1], t(9;22)(q34;q11)[BCR-ABL1] and rearrangement of the MLL gene at 11q23 in B-progenitor ALL, rearrangement of MYC in mature B-cell leukemia/lymphoma, and rearrangement of the TLX1 (HOX11), TLX3 (HOX11L2), LYL1, TAL1 and MLL genes in T-ALL. [8] [9] [10] [11] [12] These translocations frequently involve transcriptional regulators of hematopoiesis and are important initiating events in leukemogenesis, but the observations that these abnormalities are often detectable years before the onset of leukemia and usually do not alone result in leukemia in experimental models 13, 14 suggest that cooperating genetic or epigenetic lesions are required. Candidate gene studies have identified lesions such as deletion of the CDKN2A/CDKN2B (encoding the tumor suppressors p16INK4A, p14ARF and p15INK4B) and NOTCH1 in T-ALL, [15] [16] [17] [18] but until recently methods to analyze genetic alterations in a genome-wide fashion have been lacking.
Microarray platforms for detection of genetic alterations in cancer
Several microarray-based techniques for the genome-wide analysis of DNA copy number alterations (CNA) and loss-ofheterozygosity (LOH) have now become well established in the study of cancer genomics, 19 and studies of ALL are among the most advanced in the field. 20 The different platforms vary in the nature of the probes used, genomic resolution and the ability to detect LOH independently of copy number state. Array-based comparative genomic hybridization (CGH) using bacterial artificial chromosomes (BACs) has been highly informative in many tumor types, including ALL. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] BAC arrays typically use probes derived from large (up to B200 kb) fragments of human genomic DNA cloned into BAC vectors. BAC arrays now offer tiling coverage of the majority of the human genome, and generally high signal-to-noise ratio, but due to the large probe size have limited ability to detect focal CNA, 36, 37 which, as discussed below, are a hallmark of ALL. 38 Oligonucleotide arrays use short (20-100 nucleotide) probes and offer the ability to interrogate the copy number state of defined genomic regions or entire genomes at extremely high resolution, and have become more widely used than BAC arrays. Two types of oligonucleotide array are available: oligo-CGH arrays, in which test and reference DNA are labeled and hybridized simultaneously to the same array, allowing the detection of CNA but not copy-neutral LOH; and single nucleotide polymorphism (SNP) arrays that interrogate both CNA and LOH.
SNP arrays utilize oligonucleotide probes specific for each allele of hundreds of thousands of SNPs, and are widely used as a genotyping tool to enable genome-wide association studies examining associations between SNP genotype and disease susceptibility or phenotype. 39 As the intensity of probe hybridization at each SNP also reflects DNA copy number state, SNP arrays offer the ability to detect both somatic CNA in tumor samples, and inherited copy number variants (CNV) in constitutional DNA samples. By comparing SNP genotypes of tumor samples to reference samples (ideally constitutional DNA obtained from the same individual as the tumor sample) SNP arrays can detect regions of LOH. LOH may be caused by CNA (deletion or high-level gain) or may be 'copy neutral'. Such copy-neutral LOH (CN-LOH), also known as acquired uniparental disomy may reflect reduplication of a mutated or aberrantly methylated region of the genome. Identification of CN-LOH is consequently of considerable interest in cancer genomics. The ability to detect both CNA and LOH, and the modest DNA requirement of SNP arrays have resulted in increasingly widespread use of this platform in studies profiling genetic alterations in cancer. Currently available arrays (for example, from Affymetrix (Santa Clara, CA, USA) 40 and Illumina (San Diego, CA, USA) 41 ) incorporate up to B1.8 million SNP and CNV probes enabling interrogation of CNA at very high (sub-kb) resolution.
Genome-wide analysis of genetic alterations in ALL
Numerous studies have used BAC array-CGH analysis in to identify CNA in ALL, many of which are submicroscopic, or not evident on cytogenetic analysis (Table 1) . 22, 23, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] 42 These studies have delineated regions of deletion (for example, ETV6 in B-ALL), have mapped translocation breakpoints, 25, 30 have identified new CNA (for example, 9q34 duplication in T-ALL), 27 and characterized large and/or complex alterations (for example, gains of 1q and intrachromosomal amplification of chromosome 21 in B-ALL). 26, 28 However, the superior resolution of oligonucleotide array platforms, such as SNP arrays, has enabled a more detailed and comprehensive characterization of genetic alterations in ALL.
Irving et al. 43 examined a small cohort of pediatric ALL cases (N ¼ 10) using SNP arrays examining 10 000 markers, and detected LOH in the majority of cases, most commonly involving CDKN2A/B at 9p21.3. This was one of the first studies to show that SNP arrays could successfully identify LOH in cancer, although the relatively low resolution of these arrays precluded precise delineation of many of the identified regions of genetic alteration.
We and others have performed high-resolution SNP array analysis of large cohorts of pediatric ALL patients, and identified multiple novel regions of CNA and LOH in diagnostic ALL samples. 38, [44] [45] [46] [47] [48] Using Affymetrix SNP arrays interrogating over 350 000 markers at an average intermarker resolution of less than 5 Kb, we examined 242 diagnosis B-progenitor (N ¼ 192) and T-lineage (N ¼ 50) ALL samples. 38 Several key methodological aspects enabled accurate identification of somatic (tumor-acquired) lesions in this study. SNP array analysis of constitutional DNA samples was performed in conjunction with tumor samples for the majority of samples, enabling tumoracquired CNA to be definitively distinguished from inherited copy number variations, and acquired LOH from inherited regions of homozygosity. Secondly, we developed an array normalization procedure ('reference normalization') that uses SNP data only from diploid chromosomes to guide normalization of array data, which was critical to obtain accurate copy number inferences from aneuploid samples. 38, 49 Finally, we used circular binary segmentation, an automated method of identifying CNA originally developed for array-CGH data, to comprehensively identify all lesions. 50 This study identified over 50 recurring regions of CNA. As expected, we identified large genomic alterations, such as aneuploidies in hyper-and hypodiploid ALL, and gains of 1q in high hyperdiploid and unbalanced t(1;19) [TCF3-PBX1] ALL (Figure 1a) . However, most recurring regions of CNA identified were focal, with the minimal common region of loss or gain being less than 1Mb in size, and in the majority of cases targeting a single gene. The majority of focal CNA were deletional, with few focal amplifications identified (a notable exception being MYB in T-lineage ALL). The lesions targeted multiple key cellular pathways, including lymphoid differentiation (PAX5, EBF1, IKZF1, IKZF2, IKZF3, TCF3, LEF1, RAG1/2), tumor suppression (NF1, PTEN, RB1), apoptosis (BTG1), lymphocyte signaling (BTLA/CD200), microRNAs (mir-15/16) and drug responsiveness (NR3C1), in addition to genes with no known role in lymphoid development or oncogenesis (for example, ADD3, DMD) and uncharacterized genes (C20orf94). Notably, the average number of CNA was low Table 1 Key points K Genetic characterization of acute lymphoblastic leukemia (ALL) has traditionally relied on cytogenetic analysis and detection of specific translocations or mutations by molecular techniques. These remain important in diagnosis but do not explain the full genetic complexity of ALL. K Microarray based analysis of DNA copy number alterations (CNA) and loss-of-heterozygosity (LOH) can identify genetic alterations at extremely high resolution. Platforms include bacterial artificial chromosome, oligonucleotide and single nucleotide polymorphism (SNP) microarrays. SNP arrays identify CNA and copy-neutral LOH. Current platforms have a resolution of B2 million probes per array K Careful simultaneous analysis of both tumor and corresponding germline DNA is required for optimal CNA/LOH detection K Both B-progenitor and T-lineage ALL harbor recurring CNA targeting genes regulating lymphoid development, tumor suppression, cell cycle, apoptosis, lymphoid signaling and drug responsiveness. These alterations are frequently focal (less than 1 Mb) and not evident on cytogenetic analysis. K Alterations in genes regulating B-lymphoid development are present in over 60% of B-progenitor ALL, and include CNA, sequence mutations and translocations of lymphoid transcriptional factors such as PAX5, IKZF1 and EBF1. Loss-offunction of these genes accelerates leukemogenesis in experimental models, suggesting that these genetic alterations contribute to leukemogenesis in human ALL. K Genetic alterations identified in diagnosis leukemic cells, such as deletion/mutation of IKZF1, predict poor outcome in ALL K Profiling of CNA at diagnosis and relapse in ALL has identified marked evolution of genetic alterations from diagnosis to relapse, and a common clonal origin of diagnosis and relapse leukemic cells in most cases, suggesting that specific genetic changes are selected for during treatment and confer resistance to therapy K Future studies will require comprehensive analysis of sequence mutations, epigenetic profiling, and integration of genomic data from multiple genomic platforms in order to define the full complement of genomic alterations contributing to the pathogenesis of ALL, treatment failure and the identification of new therapeutic targets.
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(mean 6 per case), indicating that in most cases, ALL is not characterized by gross genomic instability. Indeed, specific mechanisms underlie the acquisition of CNA, as discussed below. Furthermore, there were significant differences in the frequency of CNA among ALL subtypes. MLL-rearranged ALL cases had less than one CNA per case, most of which occurred at the breakpoints of MLL and its fusion partners. This suggests that few cooperating lesions are required in MLL-rearranged leukemia. This is compatible with the behavior of this leukemia, which typically develops in utero and presents early in infancy.
In contrast, ETV6-RUNX1 and BCR-ABL1 leukemia both harbored over six lesions per case, suggesting the requirement for multiple additional lesions in leukemogenesis. 51 The frequency of individual CNA also differed significantly among ALL subtypes. Deletions of ADD3, C20orf94, the ETS family members ERG and ETV6, the fragile histidine triad gene FHIT, TBL1XR1, a histone cluster at 6p22.22 were common in B-ALL but rarely, if ever, observed in T-ALL. Conversely, CDKN2A/B deletion was more frequent in T-ALL (72 vs 33.9% of B-ALL cases). 38 
Mutations of genes regulating B-lymphoid development in ALL
Genes regulating normal B-lymphoid development were mutated in over 40% of B-ALL cases (Figures 1b and 2) . PAX5, which encodes a transcription factor required for B-lineage commitment and maturation, [52] [53] [54] [55] was most commonly involved, and targeted by deletion, focal amplification, translocation or sequence mutation in 31.7% of cases, a finding confirmed in other SNP array studies of ALL ( Figure 2 ). 44, 46 Approximately half of the CNA involved the entire PAX5 locus. In the remainder, a subset of exons encoding either the N-terminal, DNA-binding paired domain and/or C-terminal transactivating domains were involved. 40% of deletions involved an internal subset of exons, resulting in the expression of internally truncated transcripts that encode PAX5 proteins lacking key functional domains, or frameshifted, hypomorphic alleles. This pattern of very focal deletions involving a subset of exons, and resulting in the expression of internally truncated proteins with aberrant function, has now been observed in multiple genes in B-ALL, including IKZF1 (see below). Several cases had deletions involving C-terminal exons and extending distally to PAX5. This pattern was also observed at the breakpoints of known translocation partners in ALL (for example, MLL, ETV6, RUNX1 and TCF3) suggesting that these cases may harbor cryptic PAX5 translocations. Three translocations were identified (PAX5-ETV6, 56 ,57 PAX5-FOXP1, PAX5-ZNF521), each of which fuses the DNA-binding paired domain of PAX5 to key functional domains of partner genes that have known or putative roles in lymphoid development or oncogenesis. [58] [59] [60] [61] [62] These translocations are predicted to disrupt normal activity of PAX5 (and possibly the partner gene), and in luciferase reporter assays using a CD19 reporter, the fusions were found to act as competitive inhibitors of normal PAX5 transactivating activity. Subsequent studies have identified additional PAX5 fusions in ALL, involving multiple partner genes including ASXL1, AUTS2, BRD1, C20orf112, DACH1, ELN, HIPK1, JAK2, KIF3B, LOC392027, PML, POM121 and SLCO1B3. 47, [63] [64] [65] [66] The overall frequency of PAX5 translocations appears low (B2.6% B-ALL cases), 66 although studies comprehensively examining PAX5 translocation in large B-ALL cohorts are awaited.
Genomic resequencing of PAX5 in the St Jude study described above also identified 16 missense, insertion/deletion, splice site and frameshift mutations that clustered in the key DNA-binding and transactivating domains of PAX5. Notably, most paired domain mutations were missense, and each of these (V26G, P34Q and P80R) was predicted by structural modeling to impair the interaction of PAX5 with its DNA targets. This was confirmed using multiple in vitro assays of DNA-binding and transactivating activity. 38 In contrast, mutations involving the transactivating domain were more commonly frameshift mutations resulting in truncation of this domain, and are highly deleterious in in vitro assays. A similar frequency and pattern of PAX5 CNA and sequence mutations has been identified in other childhood B-ALL cohorts. 67 The most common mutation is P80R, which is the most deleterious of the paired domain mutations in assays of the DNA-binding and transactivating activity of PAX5.
In addition to PAX5 alterations, CNA were identified in additional regulators of B-lymphoid development, including the IKAROS family members IKZF1 (IKAROS), IKZF2 (HELIOS) and IKZF3 (AIOLOS), LEF1, TCF3 and BLNK. A high frequency of deletion of the pre-B-cell receptor gene, VPREB1, was also observed, but as this gene is located within the immunoglobulin lambda light chain locus at 22q11.22 and is frequently deleted on rearrangement of this locus, the significance of VPREB1 deletion is presently unclear. The frequency of B-pathway alterations varied significantly among ALL subtypes. All hypodiploid ALL cases harbored PAX5 alterations, with the majority also having concomitant sequence mutations and other lesions in the pathway. Interestingly, this ALL subtype has a poor prognosis, and subsequent analyses of high-risk B-progenitor childhood ALL cohorts have shown that an increasing number of lesions in this pathway is associated with poor outcome (see below). 67 One-third of ETV6-RUNX1 cases harbored focal PAX5 CNA (but no sequence mutations), and EBF1 deletion in a minority of cases, but never deletion of IKZF1. In contrast, deletion of IKZF1 is a near-obligate lesion in BCR-ABL1 ALL. 68 Few lesions in this pathway were observed in MLL-rearranged or high-hyperdiploid ALL. CNA targeting lymphoid differentiation are less frequent in T-ALL and involve early lymphoid regulators (for example, the IKAROS family) rather than B-lineage-specific genes.
The genomic and in vitro functional data described above suggest that genetic lesions targeting lymphoid development are important in the pathogenesis of ALL. This is supported by in vivo studies modeling the role of Pax5 haploinsufficiency in leukemogenesis. In a murine retroviral bone marrow transplant model of BCR-ABL1 B-progenitor ALL, 14, 69 Pax5 haploinsufficiency increases the penetrance and reduces the latency of B-ALL . 70 Additional CNA of Pax5 and Cdkn2a/b, and sequence mutations of Pax5, were observed in the resulting murine tumors, further supporting a role for these alterations in leukemogenesis. To further test the hypothesis that PAX5 is a haploinsufficient tumor suppressor, we performed chemical and retroviral mutagenesis of thymectomized mice heterozygous for a Pax5 null allele 71 using retrovirus (Moloney murine leukemia SPOTLIGHT Figure 2 Mutations in genes regulating B-lymphoid development in B-progenitor ALL. The stepwise differentiation of hematopoietic stem cells to mature B cells is shown. This process is regulated by a tightly controlled hierarchy of transcription factors that enforce B-lineage commitment and differentiation, and suppress differentiation to alternate (T-lymphoid, myeloid) lineages. These transcription factors are targeted by genetic alterations in over 60% of B-progenitor acute lymphoblastic leukemia (ALL) cases. Notably, the genetic alterations affect transcription factors controlling differentiation up to the pre-B cell stage of development, at which differentiation is arrested in many B-ALL cases. Additional known or putative B-lymphoid regulatory genes targeted less frequently in ALL include BLNK, IKZF2, IKZF3, MEF2C, RAG1/2 and SOX4.
virus) or N-ethyl-N-nitrosourea. 72 In both approaches, Pax5 loss was associated with a highly significant increase in the frequency of leukemia, and a shift from myeloid/T-lymphoid to pre-B phenotype. These data provide compelling evidence that genetic alterations resulting in a block in B-lymphoid development are key events in the pathogenesis of B-ALL. Furthermore, higher resolution SNP array studies of pediatric ALL have identified lesions targeting this pathway in two-third of cases, indicating that these alterations are important in the majority of B-ALL cases. 67 
Genomic analysis of T-lineage ALL
T-lineage ALL is also characterized by a number of sentinel chromosomal translocations, which commonly juxtapose the regulatory regions of T-cell antigen-receptor gene loci to oncogenes, and are associated with distinct gene-expression signatures. 11, 73 Genomic profiling of CNA has been equally revealing in T-ALL. BAC-array analyses have identified amplification of ABL1, which led to identification of the NUP214-ABL1 fusion that results in constitutive activation of ABL1. 74 We and others have used SNP, BAC or oligo-array CGH platforms to identify deletions resulting to dysregulated expression of TAL1 18 and PTEN 77 ) will be important to accurately classify T-ALL and examine associations with treatment outcome.
Mechanism of CNA generation in ALL
The high resolution of current SNP arrays has enabled PCR mapping and sequencing of the genomic breakpoints at sites of recurring CNA, and this has provided insights into the mechanisms of deletion in ALL. For example, the proximal and distal breakpoints of the most common IKZF1 deletion (D3-6) in B-ALL vary by only a few nucleotides, and heptamer and partially conserved nonamer recombinase activating gene (RAG) recognition sequences are present immediately internal to the deletion breakpoints. 45 This suggests that the IKZF1 deletions arise from the aberrant RAG activity, 82 and this is further supported by the presence of extra nonconsensus nucleotides between the breakpoints, compatible with the action of terminal deoxynucleotidyl transferase. This has previously been described for CDKN2A/B deletions in ALL, 83 and we have observed this pattern at the sites of other CNA in B-ALL involving PAX5, IKZF2 and IKZF3, ERG, C20orf94, BTLA/ CD200, and ADD3 (unpublished observations). This suggests that these deletions arise in a lymphoid progenitor at a stage of differentiation during which RAG1/2 are active, and that the deletions are subsequently selected for and contribute to leukemogenesis.
Copy-neutral loss-of heterozygosity (acquired uniparental disomy) in ALL CN-LOH may indicate duplication of a gene altered by point mutations or epigenetic modification within the region of LOH. Consequently, detection of CN-LOH in leukemia is an area of intense research activity. For example, CN-LOH accompanying acquisition of homozygous mutations of FLT3 and CEBPA has been described in acute myeloid leukemia. 84, 85 CN-LOH in ALL is common, and most frequently involves chromosome 9p, 38, 46 suggesting that this region may harbor a mutated or methylated tumor suppressor. However, high-resolution SNP array studies 38, 45 have shown that the majority of regions of CN-LOH at 9p harbor a focal deletion of CDKN2A/B that has been reduplicated. Thus, true CN-LOH, in which there is no discernible CNA in the region of LOH, is uncommon. Moreover the ability to accurately distinguish CN-LOH from inherited regions of homozygosity is dependent on the availability of matched constitutional samples from the same individuals. Algorithms for inferring LOH from pools of unpaired reference samples are available, but inevitably are a compromise. 86 Genetic determinants of high-risk ALL The data described above indicate that genomic alterations are critical in establishing the leukemic clone present at diagnosis. Can similar studies identify genetic alterations determining the risk of treatment failure and relapse, and potential new targets for therapy? Although relapse is most common in BCR-ABL1-positive and MLL-rearranged ALL, relapse is observed across the spectrum of ALL subtypes, particularly in adult patients, and the biologic determinants of relapse are poorly understood. Several recent SNP array studies have also shown that genetic alterations are important in determining the phenotype and risk of relapse in high-risk ALL.
Genomics of BCR-ABL1 leukemia
Expression of the constitutively active tyrosine kinase BCR-ABL1 is the hallmark of two diseases with distinct clinical manifestations and therapeutic responsiveness: chronic myeloid leukemia (CML), a myeloproliferative disease that typically responds well to kinase inhibition, 87 and BCR-ABL1-positive ALL that is highly aggressive and has a poor prognosis. 88 This dichotomy has been attributed, at least in part, to the nature of the BCR-ABL1 fusion transcript (p210 or p190/p185), 89 or the leukemia initiating cell in which the translocation arises. 90, 91 The role of cooperating genetic lesions in determining the lineage of BCR-ABL1 leukemia, and the nature of genetic lesions in influencing the transformation of chronic phase (CP) CML to acute leukemia (blast crisis), which may be of myeloid or lymphoid lineage, are incompletely understood. 92 To examine the genomic basis of lineage and disease progression of BCR-ABL1 leukemia, we expanded our previous studies to examine 43 de novo BCR-ABL1-positive ALL cases (21 pediatric and 22 adult), and 128 samples from 90 patients with CML including 64 obtained at CP (N ¼ 64), 15 at accelerated phase (AP, N ¼ 15), 32 at blast crisis (22 myeloid and 9 lymphoid) and germline samples obtained at disease remission. 45, 93 Importantly, 25 CML cases had sequential samples obtained at CP/AP and blast crisis, enabling identification of lesions acquired during disease progression.
A striking finding was deletion of IKZF1, encoding the early lymphoid transcription factor IKAROS, 94 in 36 of 43 (84%) of de novo BCR-ABL1 ALL cases. 45 Several other recurring deletions were also identified in BCR-ABL1 ALL, albeit at lower frequency, including CDKN2A/B, PAX5, C20orf94, RB1, MEF2C and EBF1. Similar to deletions of PAX5, the IKZF1 deletions were usually hemizygous and deleted either the entire IKZF1 locus or a subset of exons, most commonly coding exons 3-6,
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resulting in the expression of internally truncated IKZF1 transcripts. IKAROS is a transcription factor with N-terminal zinc fingers that mediate DNA binding, and C-terminal zinc fingers that mediate dimerization with other IKAROS family members. 95 IKAROS isoforms that lack the N-terminal, DNAbinding zinc fingers, and act as dominant negative isoforms had previously been identified in ALL, [96] [97] [98] [99] [100] [101] [102] and had been attributed to aberrant posttranscriptional splicing. 103 However, we observed absolute concordance between the extent of IKZF1 deletion and the extent of truncation of IKAROS isoforms on reverse transcription-PCR and western blotting analysis, demonstrating that the expression of aberrant IKAROS isoforms in ALL is driven by genetic alterations.
Furthermore, the pattern of CNA acquired during the progression of CP-CML to lymphoid blast crisis was highly similar to de novo BCR-ABL1 ALL. Seven of nine lymphoid blast crisis CML cases harbored alterations in genes regulating B-lymphoid development, including IKZF1 (N ¼ 6; two cases having homozygous deletions and one case a deletion and frameshift mutation), PAX5 (N ¼ 4) and EBF1 (one case with a homozygous deletion). CDKN2A/B was deleted in 6 of 9 lymphoid, but only 2 of 22 myeloid blast crisis cases. Other CNA observed in de novo BCR-ABL1 ALL were also detected in lymphoid blast crisis CML, including deletions of MEF2C, C20orf94 and HBS1L. These data indicate that cooperating genomic alterations are critical determinants of the lineage of BCR-ABL1 leukemia and progression of CML to blast crisis. Studies directly examining the role of IKZF1 alteration and other common lesions (PAX5, CDKN2A/B) in the pathogenesis and treatment resistance of BCR-ABL1 lymphoid leukemia will be of great interest.
Genetic determinants of relapse in ALL
Although treatment failure is more common in subtypes such as BCR-ABL1, MLL-rearranged and hypodiploid ALL, relapse is observed across the spectrum of ALL, and carries a poor prognosis. A logical extension of the studies of diagnosis ALL samples described above was to perform high-resolution genomic profiling of relapsed ALL, to identify genetic lesions associated with treatment failure. Two recent complementary studies have provided important insights into the genetic basis of relapse. In a study with the Children's Oncology Group as part of the National Cancer Institute TARGET (Therapeutically Applicable Research to Generate Effective Treatments) project, we used performed Affymetrix SNP array analysis of CNA/LOH, gene-expression profiling and candidate gene resequencing of a cohort of 221 childhood B-progenitor ALL cases predicted to be at high risk of relapse. 67 This cohort excluded BCR-ABL1 and hypodiploid ALL, and most cases (77%) lacked a cytogenetic alteration.
Genome-wide analysis of associations between CNA and outcome demonstrated a highly significant association between alterations of IKZF1 and relapse. Patients harboring an IKZF1 deletion or sequence mutation had a 5-year incidence of relapse of 73.4% compared to 25% for those without an alteration. Notably, this association was confirmed in an independent cohort of patients treated at St Jude, and remained significant in multivariable analyses incorporating minimal residual levels early in therapy, suggesting that detection of IKZF1 alteration will be useful in risk stratification. An additional finding was that the gene-expression profile of poor outcome, IKZF1-mutated (but BCR-ABL1-negative) cases in this study was highly similar to that of BCR-ABL1-positive ALL. This suggests that IKZF1 is an important determinant of the biology and poor outcome of both BCR-ABL1-positive and -negative ALL, and also raises the possibility that these BCR-ABL1-negative cases harbor additional mutations resulting in kinase activation.
If genetic alterations detectable in the predominant clone at diagnosis influence risk of relapse, what new lesions are acquired during progression from diagnosis to relapse? To address this, we performed SNP array analysis of 61 matched diagnosis and relapse B-progenitor (N ¼ 47) and T-lineage (N ¼ 14) samples. 104 Over 92% of cases exhibited differences in the pattern of CNA between diagnosis and relapse. Analysis of the pattern of CNA at antigen-receptor loci demonstrated that most relapse samples were clonally related to the diagnosis samples, rather than being distinct second leukemias. Remarkably, although 34% of cases showed simple clonal evolution (that is, preservation of CNA present at diagnosis and acquisition of new lesions at relapse), over 50% of samples acquired new lesions and also lost CNA present at diagnosis, yet demonstrated a common clonal origin. Furthermore, CNA-specific backtracking using genomic PCR assays showed that in the majority of cases the relapse clone was present at low levels at diagnosis. This indicates that the diagnosis and relapse clones originate from a common, prediagnosis ancestral clone, and acquire distinct CNA before emerging as the predominant clones at diagnosis or relapse. Pathway analysis of the many genes involved by relapse-acquired CNA demonstrated tumor suppression (for example, CDKN2A/B) and lymphoid development (for example, IKZF1) to be most frequently involved. Thus, the genetic basis relapse appears more complex than simple drug resistance, and further analyses examining additional types of genetic alteration in this context, such as sequence mutation, will be important to identify potential pathways for therapeutic intervention.
Future directions
The studies described above have identified a plethora of hitherto unsuspected genetic alterations in ALL, and have transformed our understanding of the genetic basis of this disease. However, much remains to be learned. Microarray platforms for the detection of CNA have evolved rapidly and current platforms contain up to 2 million probes that interrogate the genome at sub-kilobase resolutionFa 200-fold increase from the first SNP arrays used ALL. 43 It is important to note that the coverage of many genes on previous SNP arrays was suboptimal (notably IKZF1), and we have observed an increase in lesion frequency with each increase in array resolution. 105 Thus the current estimates of lesions frequency in ALL (and indeed all tumors) remain a 'lower limit', and tiling analysis of CNA is required to accurately identify all lesions. Moreover, although we now have a detailed understanding of the texture of genetic alterations in diagnostic ALL samples, studies that examine specific subtypes of high-risk ALL, and cases lacking sentinel chromosomal abnormalities are required to identify novel leukemogenic lesions, and potential targets for therapy. Relapse is particularly problematic in adult ALL, which has a lower frequency of known chromosomal alterations than pediatric ALL.
106 CNA profiling data in adult ALL is limited, 68, 107 and larger studies of this patient group are needed. Existing studies have performed genome-wide analysis of only a single class of genetic alterationFcopy number changesFand complementary genome-wide analyses of sequence mutations and epigenetic changes in ALL are required. 108 This is not a trivial undertaking, but with the rapid evolution of
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Genomic analysis of ALLnext-generation sequencing technology, 109 interrogation of DNA regions or whole genomes in cancer is now possible. Indeed, genome-wide analysis of coding mutations has been recently described in acute myeloid leukemia. 110 A potential benefit of next-generation sequencing approaches is the ability to detect copy number variation, sequence variation and structural rearrangements of cancer genomes simultaneously and in a truly genome-wide fashion. 111 As next-generation sequencing platforms can also perform transcriptional profiling 112 it is likely that they will eventually supplant microarray methodologies, 113 however the cost of analyzing large numbers of tumor genomes is currently prohibitive. Integrating massive, complex datasets from multiple complementary genomic platforms (for example, CNA, expression, microRNA and methylation) will be a formidable challenge, but necessary to examine the interaction of different genetic alterations in leukemogenesis and response to therapy. However, recent studies have made important advances into indentifying new lesions that contribute to establishment of the leukemic clone, and that influence therapeutic response. Ultimately, we can expect that these new findings will be translated into novel, less toxic targeted therapies for ALL.
